Evidence map›Paper›PMID 32112359›Full record

ReviewDrugs - real world outcomes2020

Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review.

Tamar Lasky, Bruce Carleton, Daniel B Horton, Lauren E Kelly, Dimitri Bennett, Angela S Czaja, Dina Gifkins, Osemeke U Osokogu, Ann W McMahon

Abstract readReview
In one paragraph

Review in Drugs - real world outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Concerns, beliefs and attitudes of pharmacists and pharmacy students on cannabis use in Canada.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tamar LaskyFood and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, 10903 New Hampshire Avenue, White Oak-71, Room 1253, Silver Spring, MD, 20993, USA. Tamar.lasky@fda.hhs.gov.ORCID http://orcid.org/0000-0003-4104-394X
Bruce CarletonDivision of Translational Therapeutics, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Daniel B HortonDepartment of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Lauren E KellyDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, Canada.
Dimitri BennettDepartment of Epidemiology, Takeda Pharmaceutical Company Limited, Boston, MA, USA.
Angela S CzajaDepartment of Pediatrics, Critical Care University of Colorado, School of Medicine, Denver, USA.
Dina GifkinsJanssen Research and Development, Raritan, NJ, USA.
Osemeke U OsokoguDepartment of Content and Innovation, Elsevier (Information Analytics), New York, USA.
Ann W McMahonOffice of Pediatric Therapeutics, Food and Drug Administration, Silver Spring, USA.

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
NCI NIH HHS P30 CA013330
6 · The paper itself

Abstract

backgroundThe promise of real-world evidence (RWE) is especially relevant to pediatrics, where medicines prescribed for children are often used without evidence derived from randomized clinical trials.

objectivesThe aim of this systematic review was to describe the state of RWE in pediatrics by identifying observational studies published during 2016 that used RWE to assess medication safety or effectiveness in children.

methodsAn electronic search of PubMed was combined with an extended search of references within systematic reviews and expert suggestions. Studies were included if they reported on an infant or child under 18 years with exposure to medications; assessed safety or effectiveness; specified a comparison or control group, and were published in English in 2016. Data extraction was conducted by one team member using a standardized form and reviewed by a second team member. Study quality was assessed using the GRACE checklist for rating the quality of observational studies.

resultsAfter removing duplicates, 915 citations were screened and 29 studies met the eligibility criteria. Most of the eligible studies relied on primary data collection or chart review at a single institution and did not use the growing number of administrative or electronic health record databases available. One-quarter of the studies did not use well-established statistical methods to control for confounders. No single disease group or medication predominated, and age groups ranged from infants to adolescents.

conclusionsA small body of observational studies published in 2016 were categorized by the study team as using real-world data to assess medication safety or effectiveness in children. Studies varied in age groups, diseases or conditions, and methods, and may not have fully met the FDA definition of RWE. Our review indicates that the use of RWE is not fully developed in pediatrics, and suggests an opportunity to further develop capabilities and more fully leverage administrative and electronic health record databases to study medication safety and effectiveness in children. Our systematic review appears generalizable to pediatrics broadly, and documents that the high level of activity in RWE in general has had less of an impact on pediatrics.

Identifiers

PMID32112359
PMCPMC7221095

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.